Affitech A/S and GE Healthcare Life Sciences announced
that GE Healthcare Life Sciences has executed an exclusive license for the
worldwide marketing and sales of products containing recombinant Protein L,
granted by Affitech in a patent and know-how license agreement. Under the terms
of the agreement, GE Healthcare Life Sciences agrees to pay Affitech a royalty
of the net sales of all related products sold by GE Healthcare Life Sciences.

Martin Welschof, managing director of Affitech
comments, “I am delighted that GE Healthcare Life Sciences has executed the
granted license to recombinant Protein L, which has proved to be the only
naturally occurring affinity protein useful for working with both non-protein A
binding antibodies and antibody fragments. By executing this license GE
Healthcare Life Sciences is now in a position to commercialize and widen access
to this innovative recombinant Protein L technology.”

Commenting on the execution of the recombinant Protein
L license, Catarina Flyborg, general manager BioProcess Products at GE
Healthcare Life Sciences says, “This is an important step forward for GE
Healthcare Life Sciences and will enable us to develop new technologies to help
solve some of the most difficult challenges faced by our customers in
biopharmaceutical manufacturing and in protein science research.”

GE Healthcare Life
Sciences, www.gehealthcare.com